

**RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1631**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/825,661
Applicant : Peter K. T. Pang
Filed : April 16, 2004
TC/A.U. : 1631
Examiner : Michael L. Borin

Docket No. : 3469-150
Customer No. : 6449
Confirmation No. : 8482

AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

May 24, 2007

Dear Sir:

In response to the Office Action dated December 27, 2006, please amend the above application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 4 of this paper.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-30 (Canceled)

31. (Previously presented) A method for producing a purified shark cartilage extract with anti-parathyroid hypertensive factor activity, comprising the steps of:

extracting cleaned, dried, ground shark cartilage with H₂O at a temperature between 95 -120°C for 2-4 hours,

cooling the resulting suspension to between 40-60°C, centrifuging the cooled suspension at between 5200-5700 rpm to separate the suspension into supernatant 1 and pellet,

holding the supernatant 1 in a cooling tank at 4-8°C,

extracting the pellet a second time with H₂O at a temperature between 85-120°C for 2-4 hours,

cooling the resulting suspension to between 40-60°C,

centrifuging the cooled suspension at between 5200 to 5700 rpm to separate the suspension into supernatant 2 and pellet,

pooling supernatant 1 with supernatant 2, and

spray drying the pooled supernatants to obtain the shark cartilage extract.

32. (Previously presented) The method according to claim 31, wherein said extracting steps are conducted at 95°C for 2 hours.

33. (Previously presented) The method according to claim 31, wherein a decanter centrifuge is used in said centrifuging steps.
34. (Previously presented) The method according to claim 31, further comprising concentrating the pooled supernatants until a solids content of between 8-10% is reached.
35. (Canceled).

REMARKS:

In the Office Action dated December 27, 2006, claims 21-25, in the above-identified U.S. patent application were rejected. Reconsideration of the rejections is respectfully requested in view of the above amendments and the following remarks. Claims 1-30 and 35 have been canceled and claims 31-34 remain in the application.

Claims 21-25 were rejected under 35 USC §102(b) or alternatively under 35 USC §103(a) as anticipated by or obvious over Dupont (U.S. Patent No. 5,618,925). Claims 1-30 and 35 have been canceled in order to advance the prosecution of the present application. Applicants reserve the right to pursue these claims in a divisional application. Since the remaining claims 31-34 were indicated as allowed in the office action, it is believed that the application is now in condition for allowance. If the application is not in condition for allowance, it is respectfully requested that the undersigned attorney be contacted at the telephone number below.

In the event this paper is not considered to be timely filed, the Applicant respectfully petitions for an appropriate extension of time. Any fee for such an extension together with any additional fees that may be due with respect to this paper, may be charged to Counsel's Deposit Account No. 02-2135.

Respectfully submitted,

By /Monica Chin Kitts/

Monica Chin Kitts
Attorney for Applicants
Registration No. 36,105
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040

MCK/cb